Foundation Medicine, Inc.

Foundation Medicine, Inc. is a U. S. -based company focused on advancing cancer care through innovative genomic profiling solutions that provide insights into the genetic mutations driving cancer.

Founded in 2010 in Boston, US, Foundation Medicine, Inc. specializes in genomic profiling to assist in personalized cancer treatments. The company successfully completed its IPO in September 2013, raising USD 106. 2 mn, and later secured an acquisition deal with F.

Hoffmann-La Roche Ltd for USD 780 mn in April 2015. The company has engaged in 10 deals total. Foundation Medicine specializes in advanced genomic profiling solutions designed to enhance cancer care through a comprehensive understanding of the genomic mutations that drive cancer. The company's primary offerings include FoundationOne® CDx, FoundationOne® Liquid CDx, and FoundationOne® RNA.

These products utilize next-generation sequencing to identify genomic alterations in solid tumors and circulating tumor DNA (ctDNA), enabling personalized treatment plans by matching patients with relevant targeted therapies, immunotherapies, and clinical trial options. The FoundationOne® CDx test analyzes formalin-fixed, paraffin-embedded (FFPE) tissue for mutations across 324 genes and genomic signatures, while FoundationOne® Liquid CDx and FoundationOne® RNA focus on plasma specimens and RNA fusions, respectively. The primary user base encompasses healthcare providers, biopharmaceutical companies, and research institutions primarily located in the United States, with expanding reach into international markets, including Europe and Asia. In 2017, Foundation Medicine reported revenue of USD 152.

90 mn and an EBITDA of USD -142. 41 mn. The company's revenue model is built on B2B transactions, where hospitals, oncology practices, and research institutions purchase genomic profiling tests for patient evaluation and drug development purposes. FoundationOne® CDx and FoundationOne® Liquid CDx serve as flagship products, with pricing structured around testing services rather than direct consumer sales, facilitating ongoing support and integration into clinical workflows.

Foundation Medicine aims to enhance its product offerings and expand its market reach. The company is focused on developing new genomic profiling products, although specific release dates are not detailed. It plans to penetrate international markets, targeting regions in Europe and Asia by 2023. The recent acquisition by F.

Hoffmann-La Roche Ltd, which invested USD 780 mn, is expected to support these initiatives, enhancing its capabilities in drug development and personalized medicine.